News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Mesoblast Limited In Strong Cash Position At End Of Financial Year
July 30, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Melbourne, July 30, 2009 (ABN Newswire) - Australian regenerative medicine company, Mesoblast Limited (ASX:MSB)(PINK:MBLTY), today announced that its cash position at 30 June 2009 was A$16.5 million.
Twitter
LinkedIn
Facebook
Email
Print
Asia
Australia
MORE ON THIS TOPIC
Cell therapy
Pfizer launches into autoimmune CAR T with China’s Starna in up to $2.6B deal
November 18, 2026
·
1 min read
·
Annalee Armstrong
China
In China’s shadow, Pfizer CEO calls for AI savings to bolster Big Pharma
November 18, 2026
·
1 min read
·
Annalee Armstrong
Opinion
Emerging biotech hubs step up as innovation economics evolve
November 16, 2026
·
5 min read
·
Jogin Desai
Layoffs
Biopharma layoffs rise YOY in October but sharply trend down for 2026
November 12, 2026
·
6 min read
·
Angela Gabriel